IE42969B1 - Tetracyclic compounds - Google Patents

Tetracyclic compounds

Info

Publication number
IE42969B1
IE42969B1 IE614/76A IE61476A IE42969B1 IE 42969 B1 IE42969 B1 IE 42969B1 IE 614/76 A IE614/76 A IE 614/76A IE 61476 A IE61476 A IE 61476A IE 42969 B1 IE42969 B1 IE 42969B1
Authority
IE
Ireland
Prior art keywords
compound
formula
methyl
hexahydro
azepine
Prior art date
Application number
IE614/76A
Other languages
English (en)
Other versions
IE42969L (en
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IE42969(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of IE42969L publication Critical patent/IE42969L/xx
Publication of IE42969B1 publication Critical patent/IE42969B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IE614/76A 1975-04-05 1976-03-23 Tetracyclic compounds IE42969B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Publications (2)

Publication Number Publication Date
IE42969L IE42969L (en) 1976-10-05
IE42969B1 true IE42969B1 (en) 1980-11-19

Family

ID=19823518

Family Applications (1)

Application Number Title Priority Date Filing Date
IE614/76A IE42969B1 (en) 1975-04-05 1976-03-23 Tetracyclic compounds

Country Status (17)

Country Link
US (1) US4062848A (enExample)
JP (1) JPS5942678B2 (enExample)
BE (1) BE840362A (enExample)
CA (1) CA1076571A (enExample)
CH (1) CH622261A5 (enExample)
DE (1) DE2614406A1 (enExample)
DK (1) DK142498B (enExample)
ES (2) ES446634A1 (enExample)
FI (1) FI62087C (enExample)
FR (1) FR2305986A1 (enExample)
GB (1) GB1543171A (enExample)
HU (1) HU179401B (enExample)
IE (1) IE42969B1 (enExample)
LU (1) LU74680A1 (enExample)
NL (2) NL189199C (enExample)
SE (1) SE422941B (enExample)
ZA (1) ZA761756B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) * 1986-07-31 1988-02-17 Matsushita Electric Ind Co Ltd カセツト方式文字放送受信機
JPS63177670A (ja) * 1987-01-31 1988-07-21 Fujitsu General Ltd 文字放送受信装置
JPS63215179A (ja) * 1987-03-03 1988-09-07 Fujitsu General Ltd 受信装置
IE903557A1 (en) * 1989-10-05 1991-04-10 Sankyo Co Novel tetracyclic compounds having anti-allergic and¹anti-asthmatic activities, their preparation and use
EP0539164A1 (en) * 1991-10-23 1993-04-28 Sankyo Company Limited Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ES2212550T3 (es) * 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
SK14802001A3 (sk) 1999-04-19 2002-07-02 Teva Pharmaceutical Industries Ltd. Syntéza piperazínového kruhu
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
TR200103028T2 (tr) * 1999-04-19 2002-01-21 Teva Pharmaceutical Industries Ltd. Piperazin halka içeren bileşiklerin yeni sentezi ve kristalleştirilmesi
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
WO2001025185A1 (en) * 1999-09-30 2001-04-12 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a piperazine derivative
AU6019900A (en) * 1999-11-24 2001-06-04 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
WO2001042239A1 (en) * 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound
EP1251854A2 (en) * 2000-01-19 2002-10-30 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
EP1656937A1 (en) 2000-02-11 2006-05-17 Akzo Nobel N.V. The use of mirtazapine for the treatment of sleep disorders
IN190478B (enExample) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6660730B2 (en) 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002064735A2 (en) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
EP1370549A4 (en) * 2001-03-01 2005-03-09 Teva Pharma METHOD FOR PRODUCING MIRTAZAPINE INTERMEDIATE PRODUCTS
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) * 2002-10-03 2006-08-16 Zentiva, A.S. Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
WO2004084905A2 (en) * 2003-03-24 2004-10-07 University Of Florida Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
UA83666C2 (ru) * 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
JP2008509925A (ja) * 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
JP4848704B2 (ja) * 2004-08-24 2011-12-28 住友化学株式会社 ２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法
EP1783125A4 (en) * 2004-08-24 2008-06-18 Sumitomo Chemical Co PROCESS FOR PREPARING 2- (4-METHYL-2-PHENYLPIPERAZIN-1-YL) -3-CYANOPYRIDINE
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20090306046A1 (en) * 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
WO2007008758A2 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CN1939918B (zh) * 2005-09-30 2010-09-01 北京德众万全医药科技有限公司 一种米氮平的制备方法
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
BRPI0618516A2 (pt) * 2005-11-14 2011-09-06 Sumitomo Chemical Co método para produzir 2-(4-metil-2-fenilpiperazinil-1-il)piriridina-3-metanol
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
EP1993556A1 (en) * 2006-03-06 2008-11-26 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) * 2006-06-16 2008-04-01 Organon Nv Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
WO2008030651A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
CA2675132A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5192707B2 (ja) * 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
EP2133350B1 (en) * 2007-04-11 2016-03-23 Merck Sharp & Dohme B.V. A method for the preparation of an enantiomerically pure benzazepine
US7994314B2 (en) * 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
CN101679431B (zh) * 2007-04-11 2013-08-14 Msd欧斯股份有限公司 制备四环苯并氮杂卓的对映异构体的方法
US20080255348A1 (en) * 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
JP2009018992A (ja) * 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
US20110201804A1 (en) * 2008-10-22 2011-08-18 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102432594B (zh) * 2011-11-28 2013-09-11 山东鲁药制药有限公司 一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) * 2013-10-21 2014-01-15 山东鲁药制药有限公司 一种米氮平的合成方法
CN104356133A (zh) * 2014-11-25 2015-02-18 南京工业大学 一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) * 2015-02-20 2018-12-05 株式会社トクヤマ １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法
KR102540021B1 (ko) 2020-12-02 2023-06-07 (주)유케이케미팜 대량 생산에 적합한 미르타자핀의 제조방법
CN119326767A (zh) 2023-07-21 2025-01-21 平安盐野义有限公司 用于治疗脏器纤维化相关疾病的药物组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (enExample) * 1966-03-12
NL7202963A (enExample) * 1972-03-07 1973-09-11
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation

Also Published As

Publication number Publication date
FR2305986B1 (enExample) 1980-06-13
DK142498B (da) 1980-11-10
FI760884A7 (enExample) 1976-10-06
ES459348A1 (es) 1978-03-16
DK142498C (enExample) 1981-07-06
NL940007I1 (nl) 1994-06-01
HU179401B (en) 1982-10-28
JPS51122099A (en) 1976-10-25
FI62087B (fi) 1982-07-30
ZA761756B (en) 1977-03-30
NL189199B (nl) 1992-09-01
CH622261A5 (enExample) 1981-03-31
NL7504075A (nl) 1976-10-07
DE2614406C2 (enExample) 1992-02-20
US4062848A (en) 1977-12-13
IE42969L (en) 1976-10-05
NL189199C (nl) 1993-02-01
JPS5942678B2 (ja) 1984-10-16
GB1543171A (en) 1979-03-28
SE7603931L (sv) 1976-10-06
SE422941B (sv) 1982-04-05
LU74680A1 (enExample) 1976-11-11
NL940007I2 (nl) 1994-10-17
DE2614406A1 (de) 1976-10-14
FR2305986A1 (fr) 1976-10-29
BE840362A (fr) 1976-10-04
DK142676A (enExample) 1976-10-06
FI62087C (fi) 1982-11-10
ES446634A1 (es) 1977-11-01
CA1076571A (en) 1980-04-29
AU1236176A (en) 1977-09-29

Similar Documents

Publication Publication Date Title
US4062848A (en) Tetracyclic compounds
IE922434A1 (en) Quinazoline derivatives as acetylcholinesterase inhibitors
US3845065A (en) 4-oxo-4,5-dihydrothieno(3,2-c)pyridines
IE44379B1 (en) Thiazolo (3,4-b)isoquinoline derivatives
Kajino et al. Synthesis and biological activities of new 1, 4-benzothiazine derivatives
EP0222474B1 (en) Gamma-carbolines
NL8002610A (nl) Heterocyclische verbindingen en werkwijzen voor het bereiden en toepassen van deze verbindingen.
GB1597717A (en) Pyrimido (6,1-a) isoquinolin-4-one derivatives
Hino et al. Agents Acting on the Central Nervous System.: Synthesis of 3-Phenyl-2-piperazinyl-1-benzazocines, 3-Substituted-2-piperazinyl-1-benzazepines and Related Compounds
SK1052000A3 (en) 3-substituted 3,4,5,7-tetrahydro-pyrrolo[3',4':4,5]thieno[2,3-d] pyrimidine derivatives, their preparation and use as 5ht antagonists
PL131762B1 (en) Process for preparing novel derivatives of benzodiazepine
US4447361A (en) Aryl substituted pyrido[1,4]benzodiazepines
KR20010013698A (ko) 3-치환된 피리도[3',4':4,5]티에노[2,3-ｄ]피리미딘유도체, 및 그의 제조 방법 및 용도
US3772230A (en) Polyhydro-imidazo(1,5-a)pyrimidine-3(2h)-thione and pyrido(1,2-c)pyrimidine-1-thione
JP4523160B2 (ja) 非定型抗精神病薬活性を有するピロロ［２，１−ｂ］［１，３］ベンゾチアゼピン
DK143752B (da) Analogifremgangsmaade til fremstilling af pyridobenzodiazepinoner eller farmakologisk acceptable salte deraf
NO164596B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinolinderivater.
CZ3699A3 (cs) Pyrimidinové a chinazolinové deriváty
IE51635B1 (en) 5-substituted 9-cyanomethylene-dithieno(3,4-b:4',3-e)-azepines,their preparation,and therapeutic agents which contain these compounds
US4002638A (en) Benzazepine derivatives
GB2051048A (en) Geminal Dihalogen Derivatives of Condensed Pyrimidin-4-one Compounds their Preparation and Pharmaceutical Compositions Containing them
JPS58118590A (ja) 〔１，２〕−縮合環化１，４−ベンゾジアゼピン化合物、その製法並びに該化合物を含有する、神経弛緩作用を有する医薬
FI74467C (fi) Foerfarande foer framstaellning av 1,2,3,10-tetrahydro-10-oxo-cyklopenta/d/pyrido/1,2-a/pyrimidin- och 1,2,3,4-tetrahydro-11-oxo-11h-pyrido/2,1-b/kinazolinderivat.
EP0076017B1 (en) Phenyl substituted pyrido(1,4)benzodiazepines and intermediates therefor
HU177404B (en) Process for preparing biologically active azatetracyclic compounds